腹腔热灌注化疗治疗卵巢癌恶性腹腔积液的疗效观察

目的：探讨腹腔热灌注化疗对于卵巢癌恶性腹腔积液的有效性和安全性,为临床治疗提供参考。方法：收集我院2011年6月–2014年7月期间卵巢癌恶性腹腔积液患者,共计49例,分为治疗组（腹腔热灌注顺铂化疗组）25例和对照组（单纯腹腔顺铂化疗组）24例。两组均每周灌注2次,连续治疗3周,评价治疗有效率、生活质量及毒副反应。结果：治疗组治疗有效率及KPS评分改善率分别为84.0%和84.0%,均显著高于对照组（54.2%和45.8%）,差异具有统计学意义（P〈0.05）,且未出现严重毒副反应。结论：腹腔热灌注化疗可显著提高卵巢癌恶性腹腔积液患者近期疗效及生存质量,且耐受性良好。

Clinical study of hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites

Objective： To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy （HIPEC） in ovarian cancer patients with malignant ascites. Methods： Totally 49 ovarian cancer patients were enrolled in this study from June 2011 to July 2014. A total of 25 cases in treatment group were given with HIPEC combined with cisplatin, and 24 patients were underwent intraperitoneal chemotherapy as a control group. Each patient in treatment group and control group had received six times chemotherapy during three weeks, twice one week. Changes of response rate, quality of life （KPS score） and the side effects were evaluated. Results： The response rate and improvement rate in KPS score were 84.0% and 84.0% respectively in treatment group, which showed higher than those in the control group （54.2% and 45.8%） with statistical significance （P 〈 0.05）. No severe side effect was observed during treatment. Conclusion： HIPEC is a feasible and safe treatment for ovarian carcinoma patients with malignant ascites, which can improve the short-term efficacy and quality of life.